ArticleFrontiers in oncology2026
Prognostic value of the CT-based Suidan scoring system in advanced epithelial ovarian cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the prognostic utility of the Suidan CT-based scoring system in patients with advanced epithelial ovarian cancer (AEOC) undergoing either primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). The score's correlation with residual disease and survival outcomes was examined. Methods: A total of 286 AEOC patients (PDS: 174; NACT-IDS: 112) treated between 2011 and 2020 were retrospectively analyzed. Patients were stratified by Suidan score based on clinical and radiological criteria. Surgical outcomes, progression-free survival (PFS), and overall survival (OS) were compared between treatment groups across score categories. Results: In the PDS group, increasing Suidan scores correlated with higher rates of residual disease (RD), with 100% RD observed in patients scoring ≥6. NACT-IDS significantly reduced RD rates in patients with Suidan scores ≥2. Among high-score patients (≥6), NACT-IDS was associated with significantly prolonged PFS compared to PDS (27.2 vs. 16.3 months, P = 0.04), though OS remained comparable across groups. Conclusion: The Suidan score may be a useful preoperative tool for predicting surgical and progression outcomes in AEOC. Patients with high tumor burden (score ≥6) may benefit more from NACT-IDS, highlighting the importance of CT-based stratification in guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.